微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 34.89% | -11.61% | 3.89% | 102/159 | 50.7% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 33.59% | -10.4% | 3.96% | 104/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 32.31% | -6.11% | -18.01% | 107/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 39.41% | -8.79% | -0.19% | 94/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 39.48% | -4.66% | 5.32% | 93/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 37.49% | -6.83% | 8.94% | 99/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 34.41% | -10.61% | -20.36% | 102/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 43.21% | -10.73% | 4.34% | 93/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 41.41% | -16.17% | 2.91% | 93/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 40.24% | -19.15% | 4.52% | 96/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 38.49% | -24.03% | -20.46% | 98/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 48.4% | -7.6% | -2.03% | 81/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 49.4% | -5.79% | -0.74% | 78/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 49.77% | -5.33% | -1.78% | 80/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 50.67% | 0.35% | -3.26% | 74/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 52.38% | -7.63% | -0.11% | 81/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 52.44% | -8.02% | -0.26% | 74/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 52.57% | -8.52% | 4.12% | 76/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 50.49% | -12.29% | -10.96% | 77/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 56.71% | -3.82% | -0.53% | 69/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 57.01% | -4.01% | -0.8% | 60/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 57.47% | -4.63% | -0.17% | 65/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 57.56% | 3.32% | -2.37% | 57/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 58.96% | 15.08% | -0.73% | 60/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 59.39% | 16.88% | -1.43% | 50/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 60.26% | 20.33% | 8.15% | 50/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.72% | 17.29% | 8.74% | 49/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 51.24% | 3.58% | 0.82% | 74/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 50.82% | 4.61% | 1.47% | 60/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 50.08% | 4.61% | 5.42% | 63/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 47.5% | 4.75% | -3.97% | 62/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 49.47% | 6.66% | 1.83% | 71/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 48.58% | 5.25% | 1.47% | 55/159 | 53.75% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 47.87% | 9.64% | 5.56% | 60/159 | 53.16% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 45.35% | 2% | -2.21% | 61/159 | 53.78% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 46.38% | 10.19% | 0.48% | 70/159 | 52.25% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 46.15% | 2% | 5.7% | 51/159 | 48.76% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 43.66% | 2% | 3.75% | 55/159 | 47.61% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 42.09% | 53.35% | 53.35% | 63/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |